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Abstract The X-ray crystal structure of the turkey β-
adrenoceptor has recently been determined. However,
mutations were introduced into the native receptor that
was essential for structure determination. These may cause
alterations to the receptor pharmacology. It is therefore
essential to understand the effects of these mutations on the
pharmacological characteristics of the receptor. This study
examined the pharmacological effects of both the m23
mutations and the β36 deletions, both alone and then in
combination in the β36–m23 mutant used in the crystallisa-
tion and structure determination of the turkey β-adrenoceptor.
Stable CHO-K1 cell lines were made of each of the receptor
mutants and the affinity and efficacy of ligands assessed by
3H-CGP 12177 whole cell ligand binding,
3H-cAMP
accumulation, and CRE-SPAP gene transcription assays.
The m23 mutations reduced affinity for agonists, partial
agonists and neutral antagonists by about tenfold whilst the
β36 deletions alone had no effect on ligand affinity. Both
sets of changes appeared to reduce the agonist activation of
the receptor. Both the m23 and the β36 receptors retained
two active agonist-induced receptor conformations similar to
that of the original tβtrunc receptor. The combined β36–m23
receptor bound ligands with similar affinity to the m23
receptor; however, agonist activation was only observed with
a few agonists including the catecholamines. Although the
combination of mutations severely reduced the activation
ability, the final crystallised receptor (β36–m23) was still a
fully functional receptor capable of binding agonist and
antagonist ligands and activating intracellular agonist
responses.
Keywords β-adrenoceptor.Conformational
thermostabilisation.Crystal structure.Secondary site.m23
mutations.β36 deletions
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SR59230A 1-(2-Ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahy-
dro-1-naphthalenyl]amino]-(2S)-2-propanol
tβtrunc erythrocyte turkey β-adrenoceptor with a
C-terminal truncation (Warne et al. 2008)
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Introduction
There are three turkey β-adrenoceptors (Baker 2010a). The
first one described, commonly simply referred to as the
turkey β-adrenoceptor (Bilezikian and Aurbach 1973a, b;
Schramm et al. 1972), is a Gs-coupled G protein-coupled
receptor (GPCR) that has recently been crystallised and its
structure determined to 2.7 Å resolution (Warne et al.
2008). Crystallisation required milligramme quantities of
pure, homogenous receptor, in a single conformation, that
was stable in detergent (Warne et al. 2009). The native
turkey β-adrenoceptor, which is significantly more stable
than the human β1 adrenoceptor (Serrano-Vega and Tate
2009), was still too unstable in short chain detergents for
crystallisation and it also contained flexible regions that
would prevent the formation of well-diffracting crystals.
Therefore, the receptor was modified in a series of stages to
increase both its stability and to also reduce the amount of
unstructured regions.
Initially, part of the very large C-terminus was deleted
and a C116L mutation made to make the starting construct:
tβtrunc construct (Baker 2010a; Warne et al. 2008).
Deletion of the N-terminus, made the β6 construct, which
significantly increased heterologous expression in the
baculovirus expression systems (Warne et al. 2003). This
β6 construct was then modified, firstly by introducing 6-
point mutations to increase the thermostability (the m23
mutations; Serrano-Vega et al. 2008, Fig. 1b) and secondly
residues in intracellular loop three, C-terminus and the
palmitoylation site were removed (β36 deletions; Warne et
al. 2009, Fig. 1c). Combination of the receptor truncations
(β36 deletions) and the thermostabilising mutations (m23
mutations) to form the construct β36–m23 (Fig. 1d)
allowed crystallisation and structure determination (Warne
et al. 2008, 2009).
The turkey β-adrenoceptor has several characteristics
similar to that of the human β1-adrenoceptor. If the amino
acid sequences are compared, there is 82% identity between
the transmembrane regions of both receptors with all the
residues essential for catecholamine binding being abso-
lutely conserved (Warne et al. 2008). Certain pharmaco-
logical characteristics are also very similar between the two
receptors. For example, CGP12177 is an agonist at both
receptors and its responses are similarly resistant to
inhibition by classical antagonists (Baker 2005a; 2010a;
Konkar et al. 2000; Lowe et al. 2002). In addition, both
receptors show a significant difference between their
affinity (KD value) for CGP12177 and its partial agonist
EC50 value in functional assays (Baker et al. 2003, Baker
2010a; Konkar et al. 2000). Furthermore, several ligands
appear to stimulate a two-component concentration re-
sponse curve in both receptors, suggesting that they appear
to exist in at least two agonist-induced conformations (Arch
2004; Baker et al. 2003, 2010a, b; Molenaar 2003; Walter
et al. 1984). There are, however, a few notable differences
between the receptors, for example the affinity of
CGP20712A (a human β1-selective adrenoceptor antago-
nist) and ICI118551 (a human β2-selective antagonist) are
similar at the turkey β-adrenoceptor (tβtrunc).
Structural information on GPCRs is very helpful in the
field of drug discovery and GPCR structures will poten-
tially assist in computer-aided drug design (Congreve and
Marshall 2010). However, the mutations introduced into the
native receptor that were essential for structure determina-
tion may cause alterations to the receptor pharmacology.
Therefore, for the maximum benefit to be realised from the
structure, it is essential to understand the effects of the
mutations on the pharmacological characteristics of the
receptor. Here, we examine in detail the pharmacological
effects of both the m23 mutations and the β36 deletions,
both alone and in combination in the β36–m23 mutant used
in the crystallisation and structure determination of the
turkey β-adrenoceptor (Warne et al. 2008). This study
looks at the binding characteristics of both agonists and
antagonists to assess affinity changes, functional assays to
examine receptor ligand efficacy and an analysis of the two
agonist conformations observed for some ligands.
Methods
Materials
Foetal calf serum which was from PAA Laboratories
(Teddington, Middlesex, UK). Microscint 20 scintillation
fluid from PerkinElmer (Shelton, CT, USA).
3H-CGP12177,
3H-adenine and
14C-cAMP were from Amersham Interna-
tional (Buckinghamshire, UK). Betaxolol, bisoprolol, bucin-
dolol, BRL37344, carvedilol, cimaterol, formoterol, ICI
215001, isoprenaline, L755507, salmeterol, SDZ21009,
72 Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91SR59230A, ZD2079 and ZD7114 were from Tocris Life
Sciences (Avonmouth, UK). Carazolol was from US
Biological (Swampscott, MA, USA) nebivolol and butox-
amine were a gift from Stefano Evangelista (Menarini
Ricerche Spa, Florence, Italy); zinterol was a gift from Dr.
Torsten Christ (Department of Pharmacology and Toxicolo-
gy, Dresden University of Technology, Germany.). All other
reagents were from Sigma Chemicals (Poole, Dorset, UK).
Constructs, cell lines and cell culture
As the full-length turkey β-adrenoceptor did not
express (Baker 2010a), the starting point for this study
(tβtrunc) was a C-terminally truncated version of the turkey
β-adrenoceptor that has 59 amino acids deleted from the
C-terminus (residues 425–483) and one-point mutation
C116L(Fig.1a; Warne et al. 2008). This improved functional
expression of the turkey β-adrenoceptor by threefold in the
baculovirus expression system. In order to improve expres-
sion of the receptor for structural studies, 30 amino acid were
deleted from the N-terminus (residues 2–32; construct β6;
Warne et al. 2003). The thermostability of the receptor was
increased by the inclusion of 6 point mutations introduced
into the receptor (R67S, M90V, Y227A, A282L, F327A,
F338M), which are referred to as the m23 mutations
(construct=β6–m23; Serrano-Vega et al. 2008). This in-
a) tβtrunc b) β6−m23
c) β36 d) β36-m23
Fig. 1 The amino acid sequence of the turkey β-adrenoceptor after
deletion of the C-terminal 50 amino acid residues (tβtrunc) and the
three other mutants, β6–m23, β36 and β36–m23 used in this study.
Thermostabilising point mutations are coloured blue, the original
C116L mutation in yellow and the C358A mutation to remove the
palmitoylation sites in orange
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a β6–m23 n β36 n β36–m23 n
Acebutolol −5.85 −4.91±0.05 5 −5.81±0.06 6 −4.72±0.07 7
Adrenaline −6.01 −3.81±0.07 11 −5.88±0.04 7 −3.88±0.08 6
Alprenolol −7.96 −7.40±0.05 5 −8.09±0.02 5 −7.35±0.07 7
Atenolol −5.40 −4.57±0.05 5 −5.23±0.03 6 −4.29±0.11 6
Betaxalol −6.90 −6.38±0.01 5 −6.53±0.04 6 −5.85±0.07 6
BRL35135A −6.32 −5.37±0.10 5 −6.86±0.11 5 −6.00±0.10 5
BRL37344 −5.19 −4.03±0.07 5 −5.25±0.07 6 −4.27±0.04 6
Bisoprolol −6.70 −5.66±0.05 5 −6.37±0.05 6 −5.38±0.04 6
Bupranolol −8.43 −7.78±0.04 5 −8.42±0.05 6 −7.61±0.08 6
Bucindolol −9.43 −8.71±0.02 4 −9.39±0.07 6 −8.56±0.08 6
Butoxamine −5.24 −4.93±0.07 5 −5.22±0.06 6 −4.78±0.10 5
Carazolol −10.20 −9.09±0.04 13 −10.08±0.05 6 −9.23±0.10 6
Carvedilol −9.43 −8.69±0.07 5 −9.58±0.06 5 −8.72±0.09 5
CGP20712A −7.53 −6.59±0.05 11 −7.47±0.07 8 −6.38±0.09 8
Cimaterol −7.17 −5.44±0.04 8 −7.33±0.06 9 −5.56±0.06 9
CL316243 ≥4 ≥44 ≥46 ≥46
Clenbuterol −6.74 −5.56±0.02 5 −6.89±0.06 6 −5.66±0.05 6
S-Cyanopindolol −10.89 −9.85±0.07 12 −10.81±0.07 6 −10.01±0.11 6
Denopamine −6.29 −5.13±0.04 7 −6.29±0.05 7 −4.99±0.06 6
Dobutamine −5.69 −5.40±0.01 5 −5.74±0.06 6 −5.49±0.03 6
Fenoterol −6.36 −4.33±0.04 6 −6.33±0.06 6 −4.55±0.10 8
Formoterol −7.33 −5.32±0.07 6 −7.42±0.07 6 −5.58±0.07 6
ICI118551 −7.20 −6.69±0.03 5 −7.16±0.04 6 −6.35±0.03 6
ICI215001 −5.79 −5.40±0.06 6 −5.68±0.05 6 −4.96±0.07 7
Isoprenaline −6.86 −5.13±0.05 7 −6.67±0.13 7 −5.16±0.05 7
Labetolol −7.51 −6.48±0.03 5 −7.49±0.04 6 −6.48±0.07 6
L755507 −7.17 −7.00±0.06 6 −7.40±0.06 7 −6.96±0.07 6
Metaproterenol −5.64 −3.57±0.03 6 −5.71±0.08 6 −3.49±0.08 5
Metoprolol −6.42 −5.68±0.03 6 −6.10±0.05 7 −5.27±0.07 7
Nadolol −7.99 −7.33±0.02 5 −7.98±0.03 6 −7.08±0.09 6
Noradrenaline −6.60 −4.40±0.03 6 −6.29±0.05 7 −4.53±0.11 7
Nebivolol −8.25 −8.01±0.01 4 −8.35±0.05 6 −7.73±0.09 6
Pindolol −8.55 −7.92±0.06 5 −8.56±0.06 6 −8.01±0.05 6
Pronethalol −6.85 −6.11±0.03 5 −6.93±0.04 6 −6.12±0.08 6
Propranolol −8.51 −7.92±0.05 6 −8.59±0.05 7 −7.78±0.07 7
Ractopamine −6.75 −5.82±0.06 6 −6.85±0.03 6 −5.71±0.10 6
Salbutamol −4.99 −4.16±0.06 6 −5.35±0.06 6 −4.20±0.07 6
Salmeterol −5.92 −5.31±0.05 7 −6.36±0.08 8 −5.51±0.06 6
SDZ21009 −9.27 −8.57±0.06 5 −9.41±0.04 6 −8.62±0.08 6
SR59230A −7.39 −7.10±0.05 6 −7.81±0.06 7 −7.50±0.10 7
Sotalol −6.14 −5.47±0.03 5 −6.06±0.05 6 −5.21±0.05 6
Terbutaline −4.61 ≥33 −5.07±0.08 6 ≥35
Timolol −8.76 −7.95±0.03 5 −8.90±0.04 5 −7.82±0.05 6
Tulobuterol −5.60 −4.82±0.03 5 −5.69±0.08 7 −5.00±0.10 6
Xamoterol −6.58 −5.42±0.03 6 −6.60±0.05 6 −5.27±0.09 6
ZD2079 −3.77 ≥44 −4.15±0.07 3 ≥46
ZD7114 −7.30 −6.55±0.04 5 −7.07±0.04 6 −6.28±0.08 6
Zinterol −6.40 −5.42±0.05 6 −6.52±0.06 6 −5.40±0.06 6
Table 1 Log KD values obtained
from
3H-CGP12177 whole cell
binding studies in CHO cells
stably expressing either the
tβtrunc, β36, β6–m23 or β36–
m23 adrenoceptors
Values represent mean ± SEM
for n separate experiments
aThe tβtrunc data is taken from
Baker (2010a)
74 Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91creased the thermostability of the receptor and its tolerance
to short-chain detergents by increasing kinetic barriers to the
unfolded state (Balaraman et al. 2010;S e r r a n o - V e g ae ta l .
2008). The second round of changes involved removing
potentially disordered flexible regions from the intracel-
lular portion of the receptor. As well as the 30 amino
acid deletion from the N-terminus (β6 construct), 30
amino acids were also deleted from the third intracellular
loop (residues 244–271 and 277–278), a further 56
amino acids deleted from the C-terminus (residues 369–
424) and a point mutation C358A introduced to remove
the palmitoylation site (Warne et al. 2009). These are
known as the β36 deletions (construct=β36; Warne et al.
2009). Both of these sets of changes were then combined
intothefinalproduct(β36–m23)fromwhichtheX-raycrystal
structure was determined (Fig. 1; Warne et al. 2008, 2009).
Each of these constructs were then transfected into a
Chinese hamster ovary K1 cells (CHO-K1) cell line
stably expressing a six cAMP response element – secreted
placental alkaline phosphatise reporter (CRE-SPAP)
reporter gene using Lipofectamine and OPTIMEM as per
manufacturer’s instructions and a stable cell line of each
mutation made by dilution cloning.
In order to check that there were no significant changes
in the pharmacology of the receptor during the generation
of the stable cell lines, CHO-K1 cells were also transiently
transfected with each receptor construct and the binding of
ligands examined under transient conditions (initial binding
experiments only, see “Results” section). Here, the parent
CHO-SPAP cells were transfected on day 1, the transfection
reagents removed and replaced with media on day 2, the
cells plated in to white-sided 96-well plates on day 3 and a
binding assay performed on day 4.
All cell lines were grown in Dulbecco’s modified Eagle’s
medium nutrient mix F12 containing 10% foetal calf serum
and 2 mM L-glutamine in a 37°C humidified 5% CO2:9 5 %
air atmosphere.
3H-CGP12177 whole cell binding
Cells were grown to confluence in white-sided tissue
culture treated 96-well view plates.
3H-CGP12177 whole
cell competition binding was performed as previously
described (Baker 2005b) using
3H-CGP12177 in the range
of 0.932–3.030 nM (total volume 200 μl per well). For
saturation experiments, concentrations of
3H-CGP12177 in
the range of 0.004–50.41 nM were used. The receptor
expression level of the β6–m23 line was significantly
higher than the other three cell lines, thus potentially posing
a problem of ligand depletion. The total well volume to
surface area of cells was therefore increased by carrying out
an identical method, across all four cell lines, in 24-well
plates (total volume of 2 ml per well) and 48-well plates
(total volume per well of 1.6 ml). For each individual cell
line, the different methods yielded similar KD values
3H-
CGP 12177, suggesting that ligand depletion was not a
major factor. The results presented are therefore the mean ±
SEM of the results from whole cell binding carried out in
24-, 48- and 96-well plates.
CRE-SPAP production
Cells were grown to confluence in clear plastic tissue
culture treated 96-well plates and CRE-SPAP secretion into
the media measured between 5 and 6 h after the addition of
agonist as previously described (Baker 2010a).
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Fig. 2 Inhibition of
3H-CGP12177 specific binding to whole cells by
a the antagonist timolol and b the agonist isoprenaline at each of the
turkey β-adrenoceptors mutants. Nonspecific binding was determined
by 10 μM propranolol. The concentration of 3H-CGP 12177 present
in these experiments was 1.6 nM. Data points are mean ± SE mean of
triplicate determinations. These single experiments are representative
of a five and b seven separate experiments
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Cells were grown to confluence in clear plastic tissue culture
treated 24-well plates. Following
3H-adenine pre-labelling,
3H-cAMP accumulation in the wells was measured as
previously described (Baker 2010a).
3H-cAMP was separat-
ed from other
3H-nucleotides by sequential Dowex and
alumina column chromatography as previously described
(Donaldson et al. 1988).
Data analysis
Whole cell binding–saturation binding
Saturation binding curves of the total and nonspecific
binding (as determined by the presence of 10 μM propran-
olol) were performed in order to determine the specific
binding KD value for
3H-CGP12177 and the receptor
expression level. All data points on each binding curve
were performed in quadruplicate. Specific binding (SB,
Eq. 1)o f
3H-CGP12177 at different concentrations of
3H-
CGP 12177 was fitted using the nonlinear regression
programme Prism 2.01 to the equation:
SB ¼
A   BMAX ðÞ
A þ KD ðÞ
ð1Þ
where, A is the concentration of
3H-CGP12177, BMAX is
the maximal specific binding and KD is the dissociation
constant of
3H-CGP12177. Protein was determined by
using a Pierce BCA Protein Assay Kit (Thermo Scientific,
Rockford, USA) as per manufacturers’ instructions.
Whole cell binding–competition binding
All data points on each binding curve were performed in
triplicate and each 96-well plate also contained six
Table 3 % isoprenaline maximal responses obtained from
3H-cAMP accumulation assays in CHO tβtrunc cells, β6–m23 cells, β36 cells and
β36–m23 cells, in response to a maximum concentration of ligand
tβtrunc n β6–m23 β36 n β36–m23 n
Concentration used % isop max % isop max % isop max % isop max
Metaproterenol 100 μM 124±6 4 92±3 4 141±6 4 6.1±0.3 4
Terbutaline 1 mM 120±3 4 75±3 4 100±4 4 2.3±0.3 4
BRL35135A 10 μM 99±3 4 81±4 4 80±6 4 12±1 4
ICI215001 10 μM 75±3 4 10±1 4 33±3 4 No response 4
ZD2079 100 μM 73±9 4 25±2 4 38±2 4 0.4±0.1 4
L755507 10 μM 59±8 4 5±0.3 4 10±1 4 No response 4
Bucindolol 10 μM 49±1 4 17±1 4 12±1 4 No response 4
SR59230A 1 μM 38±2 4 1.4±0.1 4 4.9±0.7 4 No response 4
Pindolol 10 μM 31±1 4 1.5±0.1 4 3.4±0.8 4 No response 4
Alprenolol 10 μM 31±2 4 1.3±0.3 4 4.9±0.8 4 No response 4
Acebutolol 100 μM 30±1 4 1.2±0.2 4 6.7±0.4 4 No response 4
Labetolol 100 μM 29±1 4 6.1±0.6 4 3.5±0.6 4 No response 4
Pronethalol 100 μM 29±1 4 4.8±0.3 4 2.4±0.7 4 No response 4
SDZ21009 10 μM 24±1 4 4.4±0.2 4 3.7±0.3 4 No response 4
Carvedilol 10 μM 12±0.4 4 0.6±0.1 4 No response 4 No response 4
Butoxamine 100 μM 7.1±0.1 4 No response No response 4 No response 4
Bupranolol 10 μM 4.4±0.2 4 No response 4 No response 4 No response 4
Timolol 10 μM 5.0±0.3 4 0.4±0.08 3 No response 4 No response 4
Nadolol 10 μM 2.6±0.3 4 No response 4 No response 4 No response 4
Atenolol 100 μM 2.1±1 4 No response 4 No response 4 No response 4
Betaxolol 100 μM 1.7±0.4 4 0.5±0.1 4 No response 4 No response 4
Nebivolol 10 μM 1.2±0.3 4 No response 4 No response 4 No response 4
Metoprolol 100 μM No response 4 No response 4 No response 4 No response 4
Sotalol 100 μM No response 4 No response 4 No response 4 No response 4
Values are mean ± SEM of n separate determinations
Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91 77determinations of total and nonspecific binding. In all cases
where a KD value is stated, the competing ligand completely
inhibited the specific binding of
3H-CGP12177.
A one-site sigmoidal response curve was then fitted to
the data using Graphpad Prism 2.01 and the IC50 was then
determined as the concentration required to inhibit 50% of
the specific binding.
% of uninhibited binding ¼ 100  
100   A ðÞ
A þ IC50
þ NS ð2Þ
where, A in the concentration of the competing ligand, IC50
is the concentration at which half of the specific binding of
3H-CGP12177 has been inhibited and NS is the nonspecific
binding.
From the IC50 value and the known concentration of
3H-CGP12177, a KD value (concentration at which half the
receptors are bound by the competing ligand) was calcu-
lated using the equation:
KD ¼
IC50
1 þ 3H   CGP12177 ½  =KD
3H   CGP12177
 ð3Þ
Functional assays—
3H-cAMP accumulation
and CRE-SPAP production
Most agonist responses were best described by a one-site
sigmoidal concentration response curve (Eq. 4)
Response ¼
EMAX   A ½ 
EC50 þ A ½ 
ð4Þ
Where EMAX is the maximum response, [A] is the
agonist concentration and EC50 is the concentration of
agonist that produces 50% of the maximal response
The affinity of antagonists was calculated (KD values)
from the shift of the agonist concentration responses in the
presence of a fixed concentration of antagonist using Eq. 5:
DR ¼ 1 þ
B ½ 
KD
ð5Þ
where, dose ratio (DR) is the ratio of the agonist
concentration required to stimulate an identical response
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Fig. 3 Correlation plots of the log KD values from
3H-CGP12177
whole cell binding for the turkey β-adrenoceptor mutants compared
with each other. Ligands are shown as either full agonists (filled
circles), partial agonists (asterisks) or antagonists (open circles).
Categorisation into these classes was performed from data in Tables 2
and 3, where ligands are defined as agonists if they stimulated more
than 85% of the response at the human β1-adrenoceptor, as partial
agonists if they stimulated 10–85% of the full response and as
antagonists if they stimulated less than 10% of a full agonist response
at the tβtrunc receptor
R
78 Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91in the presence and absence of a fixed concentration of
antagonist [B].
In experiments where three different fixed concentrations
of the same antagonist were used, Schild plots were
constructed using the following Eq. 6:
log DR   1 ðÞ ¼ log B ½    log KD ðÞ ð 6Þ
These points were then fitted to a straight line. A slope
of 1 then indicates competitive antagonism (Arunlakshana
and Schild 1959).
When CGP 12177 was used to antagonise the more
efficacious agonists where clear partial agonism was seen,
the affinity was calculated by the method of Stephenson
(1956) using Eq. 7:
KD partial agonist ¼
Y   P ½ 
1   Y
whereY ¼
A2 ½    A1 ½ 
A3
ð7Þ
where [P] in the concentration of CGP12177, [A1]i nt h e
concentration of the agonist at the point where CGP12177
alone causes the same response, [A2] is the concentration
of agonist causing a given response above that achieved
by CGP12177 and [A3] the concentration of the agonist, in
the presence CGP12177, causing the same stimulation as
[A2].
Several of the responses were however best fitted to a
two-site concentration response—Eq. 8 (e.g. Fig. 9).
%maximal stimulation ¼
A ½    N
A ½  þ EC150 ðÞ
þ
A ½   100   N ðÞ
A ½  þ EC250 ðÞ
ð8Þ
where N is the percentage of site 1, [A] is the concentration
of agonist and EC150 and EC250 are the respective EC50
values for the two agonist sites.
A two-site analysis was also used for experiments, e.g.
Fig. 10 using Eq. 9:
Response ¼ Basal þ Ag   Basal ðÞ
  1  
P ½ 
P ½  þ IC50 ðÞ

þ PAg
P ½ 
P ½  þ EC50 ðÞ

ð9Þ
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Fig. 4
3H-cAMP accumulation in response to noradrenaline, adren-
aline, clenbuterol and xamoterol in a tβtrunc cells, b β6–m23 cells, c
β36 cells and d β36–m23 cells expressed as a percentage of the
maximal response to isoprenaline in each experiment. Data points are
mean ± SE mean of triplicate determinations. Each experiment is
representative of a four, b four, c four and d three separate
experiments
R
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Ag is the response to a fixed concentration of agonist,
[P] is the concentration of CGP12177, IC50 is the
concentration of CGP12177 that inhibits 50% of the
response of the fixed agonist, PAg is the maximum
stimulation by the CGP12177 and EC50 is the concentra-
tion of competing agonist that stimulated a half maximal
CGP12177 response.
A1 0μM (maximal) isoprenaline concentration was
included in two to three wells in each plate for each
separate experiment for
3H-cAMP accumulation and six
wells of each plate for CRE-SPAP production and, to allow
agonist responses to be expressed as a percentage of the
isoprenaline maximum for each experiment. All data are
presented as mean ± SEM of triplicate determinations
(except saturation binding experiments where determina-
tions were from quadruplicate wells) and n in the text refers
to the number of separate experiments.
Results
Ligand affinity—
3H-CGP12177 whole cell binding
Binding studies were performed on both transiently trans-
fected cells and the stable cell lines to ensure that the stable
cell lines were indeed a true reflection of the pharmacology
of the transfected receptors and that no alteration of the
Table 4 Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO tβtrunc cells
tβtrunc
a Log EC50 % isop
max
n Log KD
propranolol
n Log KD
CGP20712A
Log KD
ICI118551
n Log KD
CGP12177
n
Fenoterol −8.17±0.02 120±5 3 −8.84±0.05 9 −8.20±0.00 4 −7.43±0.05 5 −9.66±0.09 9
Formoterol −8.96±0.04 115±5 5 −8.77±0.03 10 −8.20±0.10 5 −7.44±0.09 6 −9.65±0.07 8
BRL37344 −6.45±0.05 108±4 8 −8.72±0.05 6 −8.04±0.07 75 −7.25±0.08 8 −9.44±0.11 11
Cimaterol −8.63±0.05 122±5 7 −8.70±0.05 9 −8.24±0.09 5 −7.49±0.04 6 −9.54±0.07 14
Clenbuterol −7.66±0.05 102±4 12 −8.52±0.05 16 −7.82±0.09 13 −7.32±0.10 12 −9.40±0.07 15
Salmeterol −6.86±0.05 112±3 13 −8.42±0.08 10 −7.71±0.08 11 −7.15±0.10 9 −9.32±0.10 9
Salbutamol −6.33±0.07 105±4 10 −8.41±0.10 10 −7.93±0.09 6 −7.19±0.08 6 −9.34±0.11 10
Adrenaline −7.13±0.08 117±3 8 −8.38±0.12 13 −7.35±0.12 9 −6.82±0.05 7 −9.19±0.06 8
Noradrenaline −7.74±0.04 113±4 12 −8.35±0.07 16 −7.51±0.08 11 −6.98±0.07 13 −9.05±0.10 11
Isoprenaline −8.11±0.12 100 10 −8.21±0.10 18 −7.25±0.13 8 −6.72±0.12 10 −9.19±0.11 12
Dobutamine −6.53±0.06 124±5 3 −8.19±0.11 9 −7.53±0.09 5 −6.80±0.09 4 −8.94±0.08 7
CGP12177 −8.38±0.08 53±4 20 −7.23±0.12 18 −6.91±0.15 12 −6.36±0.17 11
Log KD values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ±
SEM of n separate determinations
aData table from Baker 2010a
Table 5 Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO β6–m23 cells
β6–m23 Log EC50 % isop
max
n Log KD
propranolol
n Log KD
CGP20712A
Log KD
ICI118551
n Log KD
CGP12177
n
Fenoterol −6.10±0.06 92±2 12 −8.33±0.06 9 −7.25±0.06 9 −7.03±0.04 3 −9.32±0.07 4
Formoterol −7.69±0.08 107±2 18 −8.24±0.02 13 −7.19±0.07 10 −6.97±0.04 4 −9.03±0.11 8
BRL37344 −5.37±0.07 84±2 12 −8.43±0.06 7 −7.30±0.05 6 −7.14±0.07 3 −9.18±0.07 3
Cimaterol −7.25±0.15 96±2 21 −8.29±0.04 13 −7.34±0.07 7 −6.99±0.03 4 −9.13±0.05 11
Clenbuterol −6.69±0.04 77±3 19 −8.14±0.08 11 −7.28±0.14 8 −7.10±0.04 3 −8.88±0.07 7
Adrenaline −5.81±0.08 97±2 14 −8.03±0.04 14 −7.11±0.08 3 −6.76±0.08 5 −8.71±0.09 7
Noradrenaline −6.27±0.10 98±3 15 −7.72±0.05 14 −6.87±0.08 5 −6.54±0.09 5 −8.61±0.13 7
Isoprenaline −7.39±0.11 100 21 −7.63±0.10 13 −6.74±0.13 7 −6.55±0.14 4 −8.84±0.22 5
Dobutamine −5.90±0.06 55±6 10 −7.94±0.06 4 −6.62±0.11 1 −6.71±0.04 4
CGP12177 −6.81±0.06 20±2 15 −6.03±0.11 6 −6.42±0.20 4 −5.39±0.16 6
Log KD values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ±
SEM of n separate determinations
80 Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91receptor pharmacology had taken place during the process
of making the cell line. The results from eight separate
transiently transfected cell populations (both KD of
3H-
CGP12177 from saturation studies and KD values of
betaxolol, bisoprolol, clenbuterol, CGP20712A, formoterol,
ICI118551, metoprolol and xamoterol from competition
studies) showed a similar pattern of log KD values to those
obtained from the stable cell line (Baker et al. 2008), so
only the stable cell line data are presented here.
3H-CGP12177 bound specifically to all four turkey β-
adrenoceptors mutants to give KD values (from all 96-, 48-
and 24-well plate methods combined) of 0.32±0.02 nM (n=
28) for the tβtrunc (receptor expression level of 148 fmol/mg
protein; Baker 2010a), 0.85±0.09 nM (n=27) for the β6–
m23 (2,785 fmol/mg protein), 0.34±0.02 nM (n=26) for the
β36 (134 fmol/mg protein) and 0.88±0.08 nM (n=28) for
the β36–m23 (254 fmol/mg protein) in the stable cell lines
generated. The value presented in Baker (2010a) for the
tβtrunc receptor of 0.42 nM is from the 96-well plate method
alone. The affinity of a range of other ligands (including
agonists, partial agonists and neutral agonists, see below)
was then assessed (Table 1,F i g .2).
Agonist efficacy—
3H-cAMP accumulation and CRE-SPAP
production
The agonist response to 24 ligands (seven-point concen-
tration–response curves) was examined for each of the
Table 6 Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO β36 cells
β36 Log EC50 % isop
max
n Log KD
propranolol
n Log KD
CGP20712A
Log KD
ICI118551
n Log KD
CGP12177
n
Fenoterol −7.88±0.03 91±5 3 −8.69±0.04 9 −7.72±0.16 4 −7.45±0.07 5 −9.27±0.07 9
Formoterol −8.66±0.06 90±3 4 −8.54±0.05 10 −8.10±0.06 5 −7.38±0.12 6 −9.20±0.04 9
BRL37344 −6.21±0.02 90±5 3 −8.74±0.04 6 −8.03±0.09 3 −7.41±0.05 4 −9.35±0.06 8
Cimaterol −8.51±0.02 87±3 6 −8.71±0.03 10 −7.90±0.09 5 −7.29±0.04 6 −9.24±0.05 13
Clenbuterol −7.27±0.03 72±3 6 −8.48±0.03 16 −7.72±0.07 8 −7.22±0.07 7 −8.96±0.08 10
Adrenaline −6.72±0.08 95±3 6 −7.99±0.10 13 −6.89±0.17 7 −6.77±0.09 8 −8.97±0.09 10
Noradrenaline −7.43±0.05 102±4 7 −8.00±0.05 17 −7.25±0.09 7 −6.89±0.09 9 −8.83±0.07 10
Isoprenaline −7.80±0.11 100 6 −8.04±0.11 14 −6.94±0.24 7 −6.87±0.12 8 −8.73±0.15 9
Dobutamine −6.35±0.02 102±3 3 −8.21±0.06 9 −7.33±0.05 5 −6.88±0.06 4 −8.69±0.07 7
CGP12177 −7.74±0.11 15±1 10 −6.95±0.12 12 −6.23±0.12 8 −6.32±0.17 8
Log KD values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ±
SEM of n separate determinations
Table 7 Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO β36–m23 cells
β36–m23 Log EC50 % isop
max
n Log KD
propranolol
n Log KD
CGP20712A
Log KD
ICI118551
n Log KD
CGP12177
n
Fenoterol 100 μM1 8 ± 2 5
Formoterol −5.97±0.05 90±4 4 −7.95±0.00 3 −6.95±0.06 4 −6.74±0.16 4 −8.94±0.03 4
BRL37344 No response 3
Cimaterol 10 μM3 2 ± 3 8
Clenbuterol No response 3
Adrenaline −4.67±0.03 76±3 6 −7.94±0.10 10 −6.87±0.21 3 −6.69±0.12 4
Noradrenaline −5.20±0.04 75±2 9 −6.85±0.08 9 −6.78±0.08 9 −9.10±0.11 6
Isoprenaline −6.20±0.02 100 10 −8.02±0.04 18 −6.66±0.04 16 −6.64±0.03 17 −9.05±0.03 20
Dobutamine No response 3
CGP12177 No response 11
Log KD values for propranolol, CGP20712, ICI118551 and CGP12177 as antagonists of the agonist responses are also given. Values are mean ±
SEM of n separate determinations. For fenoterol and cimaterol, the response at the maximum concentration of 100 and 10 μM respectively is
given as the top of the concentration response curve at these concentrations had not been reached
Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91 81turkey β-adrenoceptor mutants (Table 2). A further 24
ligands were examined at maximum concentrations only
(Table 3). This enabled ligands to be classified into full
agonists (those ligands that stimulated a greater than 85%
maximum response to isoprenaline in the cAMP assays at
the tβtrunc receptor), partial agonists (those that stimulat-
ed between 10–85% maximum responses at the tβtrunc
receptor) and antagonists (those ligands that stimulated
less than 10% maximum response at the tβtrunc receptor).
This allowed the study of ligand affinity to be further
examined to assess whether a particular subset of ligands
(e.g. agonists) were disproportionately affected by the
mutations (Fig. 3).
Initially, the ligands were incubated for 30 min with each
cell line; however, as many responses were found to be
very small, the response window was increased by
extending the incubation time to 5 h. This does not affect
the position (EC50 value) or maximum response of the
concentration response curve in relation to isoprenaline or
forskolin for the ligands, it merely increases the size of the
response window enabling small responses to be observed
more accurately (Baker 2010b). For example, the response
to isoprenaline at 30 min and 5 h in each lines was,
respectively: tβtrunc, −8.30±0.10 (n=8) and −8.54±0.13
(n=5); β6–m23, −7.23±0.09 (n=8) and −7.22±0.11 (n=5);
β36, −7.48±0.14 (n=8) and −7.59±0.16 (n=6); and β36–
m23, −5.84±0.02 (n=8) and −5.88±0.11 (n=6). The
numbers given in Table 2 a r et h e r e f o r eam e a no fa l lt h e
30-min and 5-h data.
Direct comparison of data between cell lines is not
possible (even in these CHO cells) because levels of
receptor expression vary and the coupling of receptors to
effectors may also differ between the different cell lines.
Nevertheless, the rank order for the efficacy of ligands
can be established by listing the ligands by the
percentage of the maximum isoprenaline response ob-
served. This was felt to be more appropriate than using
Furchgott’s efficacy ratio method (Furchgott 1966)a s
many of the ligands in this study stimulated partial agonist
responses. Tables 2 and 3 are thus the response to agonist
ligands presented in rank order of maximum response to
isoprenaline as seen in the tβtrunc receptor cell line.
Although there appear to be a few exceptions to the rank
order using this method, they are generally in the ligands
stimulating full agonist responses (e.g. dobutamine and
ractopamine which have been shown to exhibit similar
efficacy to BRL37344 and salbutamol at other β-
adrenoceptors; Baker 2010b) and probably reflects the
order in which the full agonists are presented. Generally,
however the rank order of ligands, particularly once partial
agonism is considered, is similar between tβtrunc and the
mutant receptors, with the m23 mutations and β36
deletions causing a decrease in the amount of agonism
seen and the β36–m23 receptor being the most severely
affected (Tables 2 and 3,F i g .4).
As the cell lines were all constructed from the same
parent cell line, assessing the response to forskolin
(which directly stimulates adenylyl cyclase thereby being
Table 8 Log EC50 values and % isoprenaline maximal responses obtained from CRE-SPAP production in CHO tβtrunc, β6–m23, β36 and
β36–m23 ce0lls
tβtrunc β6–m23 β36 β36–m23
Log EC50 % isop max n Log EC50 % isop max n Log EC50 % isop max n Log EC50 % isop max n
Salmeterol −6.86±0.05 112±3 13 −5.75±0.05 61±4 13 −6.57±0.02 74±3 8 No response 0 5
Terbutaline −6.09±0.08 106±4 3 −4.61±0.08 61±8 6 −5.89±0.03 78±0.3 3 No response 0 3
Salbutamol −6.33±0.07 105±4 10 −4.99±0.04 50±2 12 −5.89±0.04 64±6 3 No response 0 3
Tulobuterol −6.48±0.08 77±10 3 −5.13±0.04 29±5 7 −6.08±0.03 58±3 3 No response 0 3
ZD7114 −7.82±0.12 63±3 3 −7.15±0.04 15±3 3 −7.40±0.08 56±5 3 No response 0 3
Xamoterol −7.26±0.07 68±1 3 −5.77±0.12 21±9 3 −6.96±0.13 51±5 3 No response 0 3
Denopamine −6.70±0.07 58±3 5 10 μM1 0 ± 3 4 −6.29±0.14 40±2 4 No response 0 3
Labetolol −7.58±0.19 35±5 3 −6.56±0.04 13±2 4 −7.48±0.03 9.6±0.5 3 No response 0 3
S-Cyanopindolol −10.22±0.16 34±5 7 −7.96±0.31 16±3 3 −9.62±0.09 6.5±0.6 3 No response 0 3
Pronethalol −7.23±0.16 27±2 3 No response 0 3 No response No response 0 3
Carazolol −8.34±0.34 25±3 7 No response 0 3 No response No response 0 3
For denopamine in β6–m23 cells, the response at the maximum concentration of 10mM is given as the top of the concentration response curve
had not been reached by this maximum concentration. Values are mean ± SEM of n separate determinations
Fig. 5 CRE-SPAP production in response to clenbuterol in the absence
and presence of propranolol in a tβtrunc cells, b β6–m23 cells, c β36
cells and d β36–m23 cells. Bars represent basal CRE-SP AP production,
that in response to 10 μM isoprenaline and that in response 10, 100,
1,000 or 30, 300, 3,000 nM propranolol alone. Data points are mean ±
SEM of triplicate determinations. The Schild slopes for each experiment
are a 0.95, b 0.98 and c 1.00. Each experiment is representative of a
five, b five, c five, and d three separate experiments
b
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effector coupling and should therefore be constant in all lines)
and comparing this to isoprenaline in each line might give
information about receptor–effector coupling. For example,
for equal receptor–effector coupling, a line with very high
receptor expression would be expected to have a larger
response (compared with forskolin) and left-shifted EC50
value for the agonist.
The response to 10 μM forskolin was similar across all
four cell lines (40.1±3.9-fold over basal for tβtrunc; 37.8±
2.0-fold over basal for β36; 37.6±2.2-fold over basal for
β6–m23 and 40.7±3.9-fold over basal for β36–m23 cell
line). Interestingly, the β6–m23 cell line has a significantly
higher receptor expression level than the other three cell
lines and generated responses to isoprenaline that were far
greater than the maximum response to forskolin (iso-
prenaline maximum was 197.8±10.5% of the forskolin
response, n=8). The other cell lines generated lower total
amounts of
3H-cAMP in response to isoprenaline relative
to the forskolin response in each line, in keeping with their
lower receptor expression levels (tβtrunc isoprenaline
response was 35.9±4.5% forskolin, n=5; β36 cell line
isoprenaline response was 85.3±4.3 % of forskolin, n=6;
and the β36–m23 cell line isoprenaline response was
107.4±14.6% of the forskolin response, n=6). Thus,
despite having a lot more receptor available and being
able to stimulate a maximum response far in excess of that
in the tβtrunc line, the concentration of isoprenaline
required to stimulate a response was significantly greater
in the β6–m23 cells than in the tβtrunc cells (log EC50 −8.40
in tβtrunc cells vs. −7.23 in β6–m23 cells). This suggests
that the m23 mutations reduce the receptor’s ability to
generate a response either by reduced affinity, reduced ability
to become activated or reduced receptor–effector coupling.
Isoprenaline stimulated CRE-SPAP gene transcription
responses were 2.3- (Baker 2010a), 2.6±0.01 (n=21)-, 4.2±
0.2 (n=6)- and 2.7±0.10 (n=10)-fold over basal for tβtrunc,
β6–m23, β36 and β36–m23 receptors respectively (Tables 4,
5, 6 and 7). Once again (better seen in Table 8 where partial
agonists were examined), the m23 mutations and β36
deletions generated lower agonist responses than the tβtrunc
cell line and the β36–m23 mutant was the most severely
affected; however, the rank order of agonist efficacy
remained largely undisturbed.
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Fig. 6 CRE-SPAP production
in response to cimaterol in a
β6–m23 and b β36 cells in the
absence and presence of
CGP12177. Bars represent
basal CRE-SPAP production
that in response to 10 μMi s o -
prenaline and that in response
1, 10, 30 or 100 nM CGP12177
alone. Data points are mean ±
SEM of triplicate determinations.
Each experiment is representative
of a five and b five separate
experiments
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3H-cAMP
accumulation and CRE-SPAP production
Next, the β36 deletions and the m23 mutations were
each examined separately to determine the effects of
these mutations on the two agonist-induced conforma-
tions of the tβtrunc receptor. Several agonists stimulated
CRE-SPAP responses that were inhibited by propranolol,
CGP20712A and ICI118551 (Fig. 5,T a b l e s4, 5, 6 and 7)
in a competitive manner. CGP12177 also acted as an
antagonist, inhibiting both of these mutant receptor
responses with high affinity (Fig. 6,T a b l e s4, 5, 6 and
7). Also, CGP12177 itself stimulated a partial agonist
response at both of these mutants and in each case the log
EC50 value was significantly higher than the KD value for
CGP12177 at the mutant receptor (Fig. 7,T a b l e s4, 5, 6
and 7). In addition, these CGP12177 agonist responses
required significantly higher concentrations of proprano-
lol, CGP20712A and ICI118551 to be inhibited than the
other agonists (Fig. 7,T a b l e s4, 5, 6 and 7). This is in
keeping with two agonist-induced conformations (a
catecholamine site conformation and a secondary
CGP12177 site conformation) on each of the β36 and
β6–m23 receptor mutants.
When these mutations were combined in the β36–m23
mutantreceptor,manyagonistsdidnotstimulateanyresponse
(Fig. 5d, Tables 7 and 8). In addition, CGP12177 itself did
not stimulate any agonist response at the β36–m23 receptor
making it difficult to determine whether this mutant does
indeed have two agonist-induced conformations. However,
responses were seen to a few agonists and these responses
were inhibited by classical antagonists in a competitive
manner (propranolol, ICI118551 and CGP20712A, Fig. 8a,
Table 7). In addition, CGP12177 also inhibited these agonist
responses with high affinity in a similar manner to the
original tβtrunc receptor (Fig. 8b, Table 7).
Further evidence for two sites or conformations was
also sought by using the
3H-cAMP accumulation assay,
which has the largest response window, thus making the
detailed examination of agonist responses possible. S-
Cyanopindolol was the ligand bound to the β36–m23
receptor from which the X-ray structure was determined
(Warne et al. 2008) and it stimulated an
3H-cAMP
accumulation response that was best described by a two-
component response curve (Fig. 9a). CGP12177 and
carazolol similarly stimulated two-component response
curves (Table 9). Two component response curves were
also seen for β6–m23 and β36 receptors (Fig. 9b and c,
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Fig. 7 CRE-SPAP production
in response to CGP12177 in a
β6–m23 and b β36 cells in the
absence and presence of pro-
pranolol. Bars represent basal
CRE-SPAP production, that in
response to 10 μM isoprenaline
and that in response 1, 10 or
100 μM propranolol alone.
Data points are mean ± SEM of
triplicate determinations. Each
experiment is representative of
a five and b five separate
experiments
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CGP12177 were seen for the β36–m23 receptor (Fig. 9d).
Finally, at the original tβtrunc receptor, the stimulatory
responses to cimaterol were inhibited by low concentrations
of CGP12177, with higher concentrations of CGP12177
causing the CGP12177 agonist response (Fig. 10a). This
pattern, which can only be explained by two agonist sites or
conformations (Baker 2010a), was also seen at the β6–m23
and β36 mutant receptors (Fig. 10b, c). Similar patterns
were also seen with isoprenaline, clenbuterol and formo-
terol as agonists. Only the inhibition of the agonist
responses to isoprenaline, cimaterol and formoterol were
seen at the β36–m23 receptor (Fig. 10d).
Parent CHO cells
There was no specific binding of
3H-CGP12177 to the
parent CHO cells (i.e. CHO cells without a transfected
receptor). In addition, in the
3H-cAMP accumulation cAMP
assay and the CRE-SPAP gene transcription assay, the
parent CHO cells responded to forskolin but no responses
were seen to any of the other ligands used in this study
(Baker 2010a).
Discussion
Effect of the β36 deletions and m23 mutations on ligand
affinity
The X-ray crystal structure of the turkey β-adrenoceptor
was recently determined but several mutations were
required to stabilise the protein before the crystallisation
process could occur (Warne et al. 2008, 2009). To realise
the full potential of this structure, it is important to
understand the extent to which these mutations affects the
pharmacology. Firstly, ligand affinity was examined. The
β36 deletions made no difference to the ability of ligands to
bind (compared to the tβtrunc construct). This was true for
agonists, partial agonists and neutral antagonists. In the
correlation plot (Fig. 3b), the ligands are clearly seen to
have the same affinity for both the tβtrunc and β36
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Fig. 8 CRE-SPAP production
in response to isoprenaline in
β36–m23 cells in the absence
and presence of a propranolol
and b CGP12177. Bars repre-
sent basal CRE-SPAP produc-
tion, that in response to 10 μM
isoprenaline and that in response
10, 100 1,000 nM propranolol
or 1, 10 or 100 nM CGP12177
alone. Data points are mean ±
SEM of triplicate determina-
tions. Each experiment is repre-
sentative of a seven and b seven
separate experiments. The
Schild slopes for each experi-
ment are a 1.00 and b 1.05
Fig. 9
3H-cAMP accumulation in response to cyanopindolol in a
tβtrunc cells, b β6–m23 cells, c β36 cells and d β36–m23 cells. Bars
represent basal
3H-cAMP accumulation and that in response to 10 μM
isoprenaline. Data points are mean ± SE mean of triplicate
determinations. Each experiment is representative of a four, b 12, c
six and d three separate experiments
b
86 Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91receptor and the line of best-fit passes through the origin.
This is consistent with the view that the N-terminus, C-
terminus and most of cytoplasmic loop 3 do not interact
directly or indirectly with the ligand-binding pocket.
The m23-thermostabilising mutations resulted in a lower
affinity for all ligands–agonists, partial agonists or neutral
antagonists. The line of best fit (Fig. 3a, c) does not pass
through the origin for either β6–m23 or β36–m23 receptors
because all the ligands have about tenfold lower affinity.
Interestingly, several of the most efficacious agonists (e.g.
fenoterol, cimaterol, adrenaline, formoterol, noradrenaline
and isoprenaline) have a greater than tenfold reduction in
affinity with the m23 mutations, but this is not uniform
across all agonists.
Previous ligand binding data for β6–m23 (Serrano-Vega
et al. 2008) showed that cyanopindolol and dihydroalpre-
nolol bound to the thermostabilised receptor with similar
affinities to the unmutated receptor, whereas the binding of
the agonists isoprenaline and noradrenaline was weaker by
650- and 2,470-fold, respectively. The significant difference
between these results and the results presented here is most
likely related to the environment in which these assays were
performed. The binding experiments of Serrano-Vega et al.
(2008) were performed on Escherichia coli-expressed
receptors after solubilisation in the detergent dodecylmalto-
side, whereas the binding experiments performed here were
in living mammalian whole cells.
Effect of the β36 deletions and m23 mutations on ligand
efficacy and receptor activation
Next, the effect on ligand efficacy (or ability for receptor
activation) was investigated. As agonist efficacy depends
on many factors, including the level of receptor expression
(Clarke and Bond 1998; Kenakin 1999, 2002), it is difficult
to directly compare across cell lines. However, in both
functional assays, the catecholamines isoprenaline, adrena-
line and noradrenaline were able to stimulate agonist
response via all four receptors, including β36–m23 al-
though much higher concentrations of agonist were
required to achieve this.
As ligand affinity is reduced in the β6–m23 and β36–
m23 mutants, all other things being equal, higher concen-
trations of agonist would be expected to be required to
stimulate a response compared to the tβtrunc or β36
mutant. This was indeed observed, even in the β6–m23 line
with its higher receptor expression level. Looking further at
the other agonist ligands, with a range of efficacies from
full to weak partial agonists (e.g. Tables 3 and 8),
progressively fewer ligands were able to stimulate
agonist responses via the β36 and β6–m23 mutants
alone. For the β6–m23 receptor, the reduced ability of
the receptor to activate a response, whilst partly being
0
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Naunyn-Schmiedeberg"s Arch Pharmacol (2011) 384:71–91 87due to the reduction in affinity, is also consistent with
the theory that the m23 mutations increase the stability
of the receptor and thus increase the energy barrier
required for receptor activation. However, as the β36
deletions did not affect ligand affinity, the reduced ability
of the β36 mutant to activate responses may be a direct
effect of the mutations reducing the receptor–G-protein
interaction, consistent with extensive data implicating
cytoplasmic loop 3 and the C-terminus of GPCRs in the
receptor–G-protein activation process.
When the two were combined, the effect was even more
striking with very few agonists being able to elicit a
response from the β36–m23 mutant.
The effect of the β36 deletions and m23 mutations
on the two agonist-induced conformations
The human β1-adrenoceptor and the tβtrunc exist in two
pharmacologically active agonist-induced conformations,
consisting of a high-affinity site where catecholamines
stimulate responses and classical β-adrenoceptor antago-
nists bind with high affinity and a secondary site where
CGP12177 stimulates an agonist response and classical
antagonists have much higher affinity (Arch 2004; Baker
2005a, 2010a; Granneman 2001; Kaumann and Molenaar
2008; Konkar et al. 2000;L o w ee ta l .2002;M o l e n a a r
2003). Thus, CGP12177 binds to the tβtrunc catechol-
amine site with high affinity (KD 0.32 nM from
3H-
CGP12177 binding and 0.22–1.5 nM from antagonism of
agonist responses; Baker 2010a), but requires higher
concentrations to stimulate agonist responses (EC50
4.17 nM), suggesting that this CGP12177 agonist re-
sponse is occurring via a secondary site (Baker 2010a).
Furthermore, the concentrations of antagonists required to
inhibit the CGP12177 response are significantly higher
than those required to inhibit the other agonist responses
(Baker 2010a).
In the β6–m23 and β36 mutants, CGP12177 bound with
high affinity in both the binding assay and as an antagonist
in the functional CRE-SPAP assay suggesting that
CGP12177 binds with high affinity to the catecholamine
site on both mutants. CGP12177 also stimulated agonist
responses via both of these mutations but required a higher
concentration (higher EC50 value) than expected from its
KD value at each receptor (β6–m23 KD 0.85 nM on
binding, KD 0.48–1.45 nM on CRE-SPAP but EC50 of
155 nM on CRE-SPAP; β36 KD 0.34 nM on binding, KD
0.54–2.04 nM on CRE-SPAP but EC50 of 18.2 nM on
CRE-SPAP). Also, the concentration of antagonists re-
quired to inhibit the CGP12177 agonist responses were
significantly higher than those required to inhibit the other
agonists. This suggests that the β6–m23 receptor and the
β36 receptor both exist in at least two agonist-induced
conformations. When both mutations are combined (β36–
m23), CGP12177 was able to bind with high affinity and
antagonise catecholamine responses with high affinity,
suggesting that CGP12177 binds with high affinity cate-
cholamine site on the receptor. However, CGP12177 itself
did not simulate an agonist response via the β36–m23
receptor. This could be because either the ability of the
β36–m23 receptor to stimulate responses is too poor to
allow detection of partial agonist responses or because the
combination of the β36 deletions and the m23 mutations
has disrupted the secondary site on the turkey receptor.
Further evidence for two receptor conformations comes
from ligands that stimulate two-component concentration
response curves (Baker et al. 2003; Walter et al. 1984)—
examples at the tβtrunc receptor being CGP12177 itself, S-
cyanopindolol and carazolol (Baker 2010a). CGP12177,
carazolol and S-cyanopindolol all stimulated two-
component agonist response curves via both the β6–m23
and β36 receptors. This again suggests that neither
mutation cause a major disruption to the secondary site on
the receptor. Once again, no response was seen in the
Ligand receptor Log EC50 1 Log EC50 2 % site 1 % isoprenaline max n
S-Cyanopindolol tβtrunc −10.72±0.06 −7.84±0.13 67±1 39±1 4
β6–m23 −9.24±0.06 −6.88±0.11 44±2 9.2±1.0 12
β36 −10.42±0.36 −7.46±0.36 66±5 7.4±4.9 6
β36–m23 No response 3
Carazolol tβtrunc −9.96±0.06 −6.70±0.08 43±2 21±1 8
β6–m23 −8.69±0.24 −6.14±0.18 25±3 2.5±0.2 8
β36 −9.92±0.52 −6.52±0.21 43±10 3.4±0.5 5
β36–m23 No response 3
CGP 12177 tβtrunc −9.18±0.03 −6.73±0.17 56±3 51±3 4
β6–m23 −7.96±0.11 −5.94±0.15 35±2 11±2 11
β36 −9.26±0.15 −6.78±0.15 54±5 11±5 6
β36–m23 No response 9
Table 9 Log EC50 values and
% isoprenaline maximal
responses obtained in response
to S-cyanopindolol, carazolol
and CGP 12177 from
3H-cAMP
accumulation responses in CHO
tβtrunc, β6–m23, β36 and
β36–m23 cells
Where the response is best de-
scribed by a two-component
response, the log EC50 1 and log
EC50 2 are given along with the
% of the response occurring at
site 1. Values are mean ± SEM
of n separate determinations
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Fig. 10
3H-cAMP accumulation in response to CGP12177 in a
tβtrunc cells, b β6–m23 cells, c β36 cells and d β36–m23 cells in the
absence and presence of cimaterol. Bars represent basal
3H-cAMP
accumulation, that in response to 10 μM isoprenaline and that in
response to 3, 10, 30, 100, 300 or 1,000 nM cimaterol. Data points are
mean ± SE mean of triplicate determinations. Each experiment is
representative of a four, b six, c six and d four separate experiments
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the combination of mutations disrupted the secondary site
or because the ability of this heavily mutated receptor to
stimulate agonist responses is too reduced to be able to
examine these partial agonists.
The final evidence for two receptor conformations
comes from the inhibition of a catecholamine site agonist
response by CGP12177 at lower concentrations than those
required to stimulate the CGP12177 agonist response
(Baker 2010a; Konkar et al. 2000). When the β36 and
β6–m23 mutants were examined alone, this was also the
case. Thus CGP12177 at low concentrations inhibited, e.g.
the cimaterol response (occurring via the catecholamine
site), but higher concentrations of CGP12177 were required
to stimulate a CGP12177 agonist response, occurring via
the secondary site. This again suggests that both of these
mutant receptors exist in two agonist-induced conforma-
tions. For the combined β36–m23 mutant, CGP12177
inhibited the cimaterol response with high affinity, consis-
tent with it binding to the catecholamine site, but the lack of
the stimulation in response to CGP12177 once again
precluded the demonstration of the secondary site in the
β36–m23 receptor.
Conclusion
This detailed pharmacological analysis of the effects of the
β36 deletions and the m23 thermostabilising mutations
alone, and in combination, shows that the final crystallised
receptor (β36–m23), whilst having severely reduced ability
to activate responses compared to the original tβtrunc
receptor, is still a fully functional receptor, capable of
binding agonist and antagonist ligands and activating
intracellular agonist responses. The m23 mutations reduced
affinity for agonists, partial agonists and neutral antagonists
whilst the β36 deletions alone had no effect on ligand
affinity. Both sets of changes appeared to reduce the agonist
activation of the receptor—the β36 deletions most likely by
reducing receptor–G-protein activation and the m23 muta-
tions by both reducing ligand affinity and receptor
activation (most likely by the increased receptor stability
and thus an increased activation energy requirement).
Finally, both the β6–m23 and the β36 receptors retained
two active agonist-induced receptor conformations similar
to that of the original tβtrunc receptor, although due to the
severely reduced activation ability of the β36–m23 mutant
receptor, this feature is difficult to assess in the final
combined mutant.
Thus, the original contention that the β36–m23
receptor is preferentially in an antagonist-binding con-
formation appears to be more complex than previously
anticipated, not least because only a proportion of the
agonists tested showed a marked reduction in affinity
compared to the antagonists. The pharmacological char-
acterisation also suggests that the structure of β36–m23
with cyanopindolol bound may represent the receptor
bound with a weak partial agonist. Finally, this work
provides a solid foundation for the analysis of further
structuresofthe mutatedturkeyβ-adrenoceptor withdifferent
bound ligands.
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